EVASÃO NOS CURSOS DO PROEJA: UM ESTUDO DE CASO NO IFRJ.

O Curso de Manutenção e Suporte em Informática Integrado ao Ensino Médio na Modalidade de Jovens e Adultos, oferecido no Campus Rio de Janeiro do Instituto Federal de Educação, Ciência e Tecnologia do RJ(IFRJ), tem como proposta a formação de jovens e adultos que não tiveram oportunidade de concluir a Educação Básica em época oportuna. O curso tem apresentado baixa procura e elevado índice de evasão. Diante desta situação, chegou-se a seguinte questão: Quais ações organizacionais podem ser realizadas para possibilitar a alteração desse cenário? Visando responder à questão problemática da evasão foi estruturado o seguinte objetivo principal: Realizar um diagnóstico sobre permanência, evasão escolar e elaborar um Plano de Ação Educacional para reduzir a evasão no curso de MSI-CRJ do IFRJ contribuindo para o alcance das metas organizacionais e sociais. Como metodologia foi realizada pesquisa qualitativa tendo como instrumentos de coleta de dados pesquisa documental, revisão bibliográfica e entrevistas semiestruturadas. O estudo utilizou a análise de conteúdo e posterior categorização dos dados. A pesquisa apresentou como resultado a elaboração de Plano de Ação Educacional

AVALIAÇÃO DA EVASÃO ESCOLAR NO CURSO DE MANUTENÇÃO E SUPORTE EM INFORMÁTICA INTEGRADO AO ENSINO MÉDIO, NA MODALIDADE DE EDUCAÇÃO DE JOVENS E ADULTOS NO CAMPUS RJ DO INSTITUTO FEDERAL DE EDUCAÇÃO, CIÊNCIA E TECNOLOGIA DO RIO DE JANEIRO (IFRJ)

O Curso de Manutenção e Suporte em Informática Integrado ao Ensino Médio na Modalidade de Jovens e Adultos, oferecido no Campus Rio de Janeiro do Instituto Federal de Educação, Ciência e Tecnologia do RJ(IFRJ), tem como proposta a formação de jovens e adultos que não tiveram oportunidade de concluir a Educação Básica em época oportuna. O curso tem baixa procura e elevado índice de evasão. Diante desta situação, chegou-se a seguinte questão: Quais ações organizacionais podem ser realizadas para possibilitar a alteração desse cenário. Visando responder à questão problemática da evasão foi estruturado o seguinte objetivo principal: Realizar um diagnóstico sobre permanência e evasão escolar e elaborar um Plano de Ação Educacional para reduzir a evasão no curso de MSI-CRJ do IFRJ contribuindo para o alcance das metas organizacionais e sociais. Como metodologia foi realizada pesquisa qualitativa tendo como instrumentos de coleta de dados pesquisa documental, revisão bibliográfica e entrevistas semiestruturadas. O estudo utilizou a análise de conteúdo e posterior categorização dos dados. A pesquisa apresentou como resultado a elaboração de Plano de Ação Educacional, constituído de ações para diminuir a evasão escolar no curso de MSI-CRJ e alcançar os resultados organizacionais e sociais planejados

EFEITO TOXICOLÓGICO DE QUATRO PRODUTOS QUÍMICOS UTILIZADOS NA PROFILAXIA DE PEIXE ORNAMENTAL AMAZÔNICO

The objective of this study was to determine the acute toxicity of chemotherapeutic drugs used to diseases control in ornamental fish cardinal tetra (Paracheirodon axelrodi). The fish were exposed to four chemicals: formalin, oxytetracycline, copper sulfate and malachite green. Four experiments were performed, distributed in a completely randomized design with seven concentrations of product test (formalin, oxytetracycline, copper sulfate and malachite green), a control and three repetitions. A static system with five fish per recipient containing 2 L of water for 96 hours was used. The estimated lethal concentration 50% (LC initial (I) 50-96h) were 67.94 mg.L-1, 3.83 mg.L-1, 1.65 mg.L-1 and 0.85 mg.L-1 to formalin, oxytetracycline, copper sulfate and malachite green, respectively. Thus the present study considered the formalin low toxicity for the cardinal tetra and the copper sulfate, oxytetracycline and malachite green are moderately toxic.Keywords: ornamental fish; fish diseases; chemotherapeutic; concentration lethal.O objetivo deste estudo foi determinar a toxicidade aguda de fármacos quimioterápicos utilizados para o controle de doenças em peixes cardinais ornamentais (Paracheirodon axelrodi). Os peixes foram expostos a quatro produtos químicos: formalina, oxitetraciclina, sulfato de cobre e verde malaquita. Foram realizados quatro experimentos, distribuídos em delineamento inteiramente aleatorizado com sete concentrações do produto teste (formalina, oxitetraciclina, sulfato de cobre e verde malaquita), um controle e três repetições. Utilizou-se um sistema estático com cinco peixes por recipiente contendo 2 L de água durante 96 horas. Foram estimadas as concentrações letais 50% (LC inicial (I) 50-96h) de 67,94 mg.L-1, 3,83 mg.L-1, 1,65 mg.L-1 e 0,85 mg.L-1 para formalina, oxitetraciclina, sulfato de cobre e verde de malaquita, respectivamente. Assim, no presente estudo a formalina foi considerada de baixa toxicidade para o tetra cardinal e o sulfato de cobre, oxitetraciclina e verde malaquita são moderadamente tóxicos.Palavras-chave: Peixe ornamental, doenças de peixes, quimioterápicos, concentração letal

Volume 43, Number 3, September 2023 OLAC Newsletter

Digitized September 2023 issue of the OLAC Newsletter

Prospective Validation of the Emergency Heart Failure Mortality Risk Grade for Acute Heart Failure: The ACUTE Study

Background: Improved risk stratification of acute heart failure in the emergency department may inform physicians\u27 decisions regarding patient admission or early discharge disposition. We aimed to validate the previously-derived Emergency Heart failure Mortality Risk Grade for 7-day (EHMRG7) and 30-day (EHMRG30-ST) mortality. Methods: We conducted a multicenter, prospective validation study of patients with acute heart failure at 9 hospitals. We surveyed physicians for their estimates of 7-day mortality risk, obtained for each patient before knowledge of the model predictions, and compared these with EHMRG7 for discrimination and net reclassification improvement. We also prospectively examined discrimination of the EHMRG30-ST model, which incorporates all components of EHMRG7 as well as the presence of ST-depression on the 12-lead ECG. Results: We recruited 1983 patients seeking emergency department care for acute heart failure. Mortality rates at 7 days in the 5 risk groups (very low, low, intermediate, high, and very high risk) were 0%, 0%, 0.6%, 1.9%, and 3.9%, respectively. At 30 days, the corresponding mortality rates were 0%, 1.9%, 3.9%, 5.9%, and 14.3%. Compared with physician-estimated risk of 7-day mortality (PER7; c-statistic, 0.71; 95% CI, 0.64-0.78) there was improved discrimination with EHMRG7 (c-statistic, 0.81; 95% CI, 0.75-0.87; P=0.022 versus PER7) and with EHMRG7 combined with physicians\u27 estimates (c-statistic, 0.82; 95% CI, 0.76-0.88; P=0.003 versus PER7). Model discrimination increased nonsignificantly by 0.014 (95% CI, -0.009-0.037) when physicians\u27 estimates combined with EHMRG7 were compared with EHMRG7 alone (P=0.242). The c-statistic for EHMRG30-ST alone was 0.77 (95% CI, 0.73-0.81) and 30-day model discrimination increased nonsignificantly by addition of physician-estimated risk to 0.78 (95% CI, 0.73-0.82; P=0.187). Net reclassification improvement with EHMRG7 was 0.763 (95% CI, 0.465-1.062) when assessed continuously and 0.820 (0.560-1.080) using risk categories compared with PER7. Conclusions: A clinical model allowing simultaneous prediction of mortality at both 7 and 30 days identified acute heart failure patients with a low risk of events. Compared with physicians\u27 estimates, our multivariable model was better able to predict 7-day mortality and may guide clinical decisions. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02634762

Antileishmanial activity of meroditerpenoids from the macroalgae Cystoseira baccata

The development of novel drugs for the treatment of leishmaniases continues to be crucial to overcome the severe impacts of these diseases on human and animal health. Several bioactivities have been described in extracts from macroalgae belonging to the Cystoseira genus. However, none of the studies has reported the chemical compounds responsible for the antileishmanial activity observed upon incubation of the parasite with the aforementioned extracts. Thus, this work aimed to isolate and characterize the molecules present in a hexane extract of Cystoseira baccata that was found to be bioactive against Leishmania infantum in a previous screening effort. A bioactivity-guided fractionation of the C. baccata extract was carried out and the inhibitory potential of the isolated compounds was evaluated via the MIT assay against promastigotes and murine macrophages as well as direct counting against intracellular amastigotes. Moreover, the promastigote ultrastructure, DNA fragmentation and changes in the mitochondrial potential were assessed to unravel their mechanism of action. In this process, two antileishmanial meroditerpenoids, (3R)- and (3S)-tetraprenyltoluquinol (1a/1b) and (3R)- and (3S)-tetraprenyltoluquinone (2a/2b), were isolated. Compounds 1 and 2 inhibited the growth of the L. infantum promastigotes (IC50 = 44.9 +/- 4.3 and 94.4 +/- 10.1 mu M, respectively), inducing cytoplasmic vacuolization and the presence of coiled multilamellar structures in mitochondria as well as an intense disruption of the mitochondrial membrane potential. Compound 1 decreased the intracellular infection index (IC50 = 25.0 +/- 4.1 mu M), while compound 2 eliminated 50% of the intracellular amastigotes at a concentration > 88.0 mu M. This work identified compound 2 as a novel metabolite and compound 1 as a biochemical isolated from Cystoseira algae displaying antileishmanial activity. Compound 1 can thus be an interesting scaffold for the development of novel chemotherapeutic molecules for canine and human visceral leishmaniases studies. This work reinforces the evidence of the marine environment as source of novel molecules. (C) 2017 Elsevier Inc. All rights reserved.Portuguese FCT CCMAR/Multi/04326/2013FAPESP [2013/16297-2, 2015/11936-2]CNPq [470853/2012-3]FCT doctoral grants [ SFRH/BD/105541/2014 ]FCT Investigator Programme [IF/00049/2012]info:eu-repo/semantics/publishedVersio

Design-Based Research in CALL

The purpose of this volume is to expand and refine our understanding of the use of design-based research (DBR) in CALL by contributing to the growing body of literature in this area. We have tried our best to strike a balance between theoretical considerations and concrete examples of DBR. The first section of this volume focuses on theoretical perspectives and ideas that can inform the use of DBR in CALL. The second section contains studies that illustrate DBR through concrete instances of its operationalization. We hope this volume will be a useful source of information and inspiration for those considering to further explore DBR in CALL. For updates on DBR in CALL, please visit the companion site to this volume: https://sites.google.com/site/designbasedresearch/https://lib.dr.iastate.edu/language_books/1006/thumbnail.jp

Azimuthal anisotropy of neutral pion production in Au+Au collisions at sqrt(s_NN) = 200 GeV: Path-length dependence of jet quenching and the role of initial geometry

We have measured the azimuthal anisotropy of pi0's for 1 < pT < 18 GeV/c for Au+Au collisions at sqrt s_NN = 200 GeV. The observed anisotropy shows a gradual decrease in 3 < pT < 7 - 10 GeV/c, but remains positive beyond 10 GeV/c. The magnitude of this anisotropy is under-predicted, up to at least 10 GeV/c, by current perturbative QCD (pQCD) energy-loss model calculations. An estimate of the increase in anisotropy expected from initial-geometry modification due to gluon saturation effects and initial-geometry fluctuations is insufficient to account for this discrepancy. Calculations which implement a path length dependence steeper than what is implied by current pQCD energy-loss models, show reasonable agreement with the data.Comment: 384 authors, 6 pages text, 3 figures. Submitted to Phys. Rev. Lett. Plain text data tables for the points plotted in figures for this and previous PHENIX publications are (or will be) publicly available at http://www.phenix.bnl.gov/papers.htm

Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency

Purpose Lamb-Shaffer syndrome (LAMSHF) is a neurodevelopmental disorder described in just over two dozen patients with heterozygous genetic alterations involving SOX5, a gene encoding a transcription factor regulating cell fate and differentiation in neurogenesis and other discrete developmental processes. The genetic alterations described so far are mainly microdeletions. The present study was aimed at increasing our understanding of LAMSHF, its clinical and genetic spectrum, and the pathophysiological mechanisms involved. Methods Clinical and genetic data were collected through GeneMatcher and clinical or genetic networks for 41 novel patients harboring various types ofSOX5 alterations. Functional consequences of selected substitutions were investigated. Results Microdeletions and truncating variants occurred throughout SOX5. In contrast, most missense variants clustered in the pivotal SOX-specific high-mobility-group domain. The latter variants prevented SOX5 from binding DNA and promoting transactivation in vitro, whereas missense variants located outside the high-mobility-group domain did not. Clinical manifestations and severity varied among patients. No clear genotype-phenotype correlations were found, except that missense variants outside the high-mobility-group domain were generally better tolerated. Conclusions This study extends the clinical and genetic spectrum associated with LAMSHF and consolidates evidence that SOX5 haploinsufficiency leads to variable degrees of intellectual disability, language delay, and other clinical features

Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study

BACKGROUND: Recombinant human erythropoietin (EPO) is used for the treatment of last stage renal anemia. A new EPO preparation was obtained in Cuba in order to make this treatment fully nationally available. The aim of this study was to compare the pharmacokinetic, pharmacodynamic and safety properties of two recombinant EPO formulations in patients with anemia due to end-stage renal disease on hemodialysis. METHODS: A parallel, randomized, double blind study was performed. A single 100 IU/Kg EPO dose was administered subcutaneously. Heberitro (Heber Biotec, Havana, formulation A), a newly developed product and Eprex (CILAG AG, Switzerland, formulation B), as reference treatment were compared. Thirty-four patients with anemia due to end-stage renal disease on hemodialysis were included. Patients had not received EPO previously. Serum EPO level was measured by enzyme immunoassay (EIA) during 120 hours after administration. Clinical and laboratory variables were determined as pharmacodynamic and safety criteria until 216 hours. RESULTS: Both groups of patients were similar regarding all demographic and baseline characteristics. EPO kinetics profiles were similar for both formulations; the pharmacokinetic parameters were very close (i.e., AUC: 4667 vs. 4918 mIU.h/mL; Cmax: 119.1 vs. 119.7 mIU/mL; Tmax: 13.9 vs. 18.1 h; half-life, 20.0 vs. 22.5 h for formulations A and B, respectively). The 90% confidence intervals for the ratio between both products regarding these metrics were close to the 0.8 – 1.25 range, considered necessary for bioequivalence. Differences did not reach 20% in any case and were not determined by a formulation effect, but probably by a patients' variability effect. Concerning pharmacodynamic features, a high similitude in reticulocyte counts increments until 216 hours and the percentage decrease in serum iron until 120 hours was observed. There were no differences between formulations regarding the adverse events and their intensity. The more frequent events were pain at injection site (35.3%) and hypertension (29%). Additionally, further treatment of the patients with the study product yielded satisfactory increases in hemoglobin and hematocrit values. CONCLUSION: The formulations are comparable. The newly developed product should be acceptable for long-term application